The Ontario Health Technology Advisory Committee (OHTAC) has recommended against publicly funding robotic surgery for prostate cancer.

OHTAC determined there was not enough evidence that the minimally invasive procedure is better than traditional open surgery to justify the increased price of $6,000 per patient.

Read article 1 here.

Read article 2 here.

Leave a Comment

Scroll to Top